Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Summary

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

Timeline

Start

2006-12-29

Primary completion

2009-06-30

Completion

2009-06-30

Outcome

Outcome not reported

Stopped (Enrollment): “Sponsor stopped enrollment at 50 of 70 planned patients because an activity signal had been observed in lymphoma and further enrollment would not add significantly to interpretation of efficacy or safety.”

Drugs

Indications